These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11576847)

  • 1. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer.
    Einbeigi Z; Bergman A; Kindblom LG; Martinsson T; Meis-Kindblom JM; Nordling M; Suurküla M; Wahlström J; Wallgren A; Karlsson P
    Eur J Cancer; 2001 Oct; 37(15):1904-9. PubMed ID: 11576847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
    Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
    Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
    Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
    Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
    Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M
    Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
    Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
    Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
    Chang-Claude J; Dong J; Schmidt S; Shayeghi M; Komitowski D; Becher H; Stratton MR; Royer-Pokora B
    J Med Genet; 1998 Feb; 35(2):116-21. PubMed ID: 9507390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
    Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
    Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
    Sarantaus L; Auranen A; Nevanlinna H
    Int J Oncol; 2001 Apr; 18(4):831-5. PubMed ID: 11251181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
    Vehmanen P; Friedman LS; Eerola H; McClure M; Ward B; Sarantaus L; Kainu T; Syrjäkoski K; Pyrhönen S; Kallioniemi OP; Muhonen T; Luce M; Frank TS; Nevanlinna H
    Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
    Kumar BV; Lakhotia S; Ankathil R; Madhavan J; Jayaprakash PG; Nair MK; Somasundaram K
    Cancer Biol Ther; 2002; 1(1):18-21. PubMed ID: 12170759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a founder BRCA2 mutation in Sardinian breast cancer families.
    Monne M; Piras G; Fancello P; Santona MC; Uras A; Landriscina G; Mastio G; Gabbas A
    Fam Cancer; 2007; 6(1):73-9. PubMed ID: 17216544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and benefits of diagnosing familial breast cancer.
    Heimdal K; Maehle L; Møller P
    Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
    Lancaster JM; Carney ME; Gray J; Myring J; Gumbs C; Sampson J; Wheeler D; France E; Wiseman R; Harper P; Futreal PA
    Br J Cancer; 1998 Dec; 78(11):1417-20. PubMed ID: 9836472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
    Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
    Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
    Arver B; Borg A; Lindblom A
    Genet Test; 2001; 5(1):1-8. PubMed ID: 11336395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
    Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
    Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.